Beyond Air (XAIR) Stock Overview
A commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
XAIR Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Beyond Air, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.58 |
| 52 Week High | US$5.84 |
| 52 Week Low | US$0.43 |
| Beta | 0.53 |
| 1 Month Change | -18.69% |
| 3 Month Change | -49.83% |
| 1 Year Change | -86.13% |
| 3 Year Change | -99.48% |
| 5 Year Change | -99.43% |
| Change since IPO | -99.54% |
Recent News & Updates
XAIR: Later Regulatory Decision Will Still Support Long Term Upside Potential
Analysts have cut their price target on Beyond Air to $2 from $6, citing reduced sales estimates and a longer timeline for potential FDA approval of the second generation LungFit PH system as key reasons for the reset. Analyst Commentary Bullish Takeaways Bullish analysts still point to the second generation LungFit PH system as the main potential driver for higher long term revenue and margin expansion, which they see as central to justifying a higher valuation over time.
XAIR: Later FDA Decision Will Still Unlock Key Future Inflection
Narrative Update The analyst consensus price target for Beyond Air has shifted to $2, down from $6, as analysts point to reduced near term sales assumptions and a later FDA decision timeline for the second generation LungFit PH system, while still highlighting its potential importance for future revenue growth and profitability. Analyst Commentary Recent Street research reflects a more cautious stance on Beyond Air, with bearish analysts recalibrating expectations around both timing and scale of potential revenue from the second generation LungFit PH system.XAIR: Extended FDA Timeline Will Still Set Up Key Future Inflection
Analysts have cut their price target for Beyond Air to $2 from $6, citing revised sales timelines, with FDA approval for the second generation LungFit PH system now expected at the end of 2026, while still viewing that potential commercialization as central to future revenue growth and profitability. Analyst Commentary Recent price target revisions highlight a clear divide between long term optimism around LungFit PH and shorter term caution around execution and timing.XAIR: Future Regulatory Milestone And Capital Raise Will Underpin Potential Upside
Analysts have cut their price target on Beyond Air to $2 from $6, citing updated sales estimates and a later expected FDA decision for the second generation LungFit PH system as key drivers of their revised outlook. Analyst Commentary Bearish analysts are signaling a more cautious stance on Beyond Air, with the latest research move cutting the price target to $2 from $6 and explicitly tying that change to revised expectations around the LungFit PH opportunity and timing.Recent updates
XAIR: Later Regulatory Decision Will Still Support Long Term Upside Potential
Analysts have cut their price target on Beyond Air to $2 from $6, citing reduced sales estimates and a longer timeline for potential FDA approval of the second generation LungFit PH system as key reasons for the reset. Analyst Commentary Bullish Takeaways Bullish analysts still point to the second generation LungFit PH system as the main potential driver for higher long term revenue and margin expansion, which they see as central to justifying a higher valuation over time.XAIR: Later FDA Decision Will Still Unlock Key Future Inflection
Narrative Update The analyst consensus price target for Beyond Air has shifted to $2, down from $6, as analysts point to reduced near term sales assumptions and a later FDA decision timeline for the second generation LungFit PH system, while still highlighting its potential importance for future revenue growth and profitability. Analyst Commentary Recent Street research reflects a more cautious stance on Beyond Air, with bearish analysts recalibrating expectations around both timing and scale of potential revenue from the second generation LungFit PH system.XAIR: Extended FDA Timeline Will Still Set Up Key Future Inflection
Analysts have cut their price target for Beyond Air to $2 from $6, citing revised sales timelines, with FDA approval for the second generation LungFit PH system now expected at the end of 2026, while still viewing that potential commercialization as central to future revenue growth and profitability. Analyst Commentary Recent price target revisions highlight a clear divide between long term optimism around LungFit PH and shorter term caution around execution and timing.XAIR: Future Regulatory Milestone And Capital Raise Will Underpin Potential Upside
Analysts have cut their price target on Beyond Air to $2 from $6, citing updated sales estimates and a later expected FDA decision for the second generation LungFit PH system as key drivers of their revised outlook. Analyst Commentary Bearish analysts are signaling a more cautious stance on Beyond Air, with the latest research move cutting the price target to $2 from $6 and explicitly tying that change to revised expectations around the LungFit PH opportunity and timing.XAIR: Later FDA Decision Will Still Support Long Term Upside Potential
Analysts have cut their average price target for Beyond Air from about $12.33 to $8.67, reflecting updated expectations for slower revenue growth, a higher discount rate, and a higher future P/E multiple as they factor in revised sales estimates tied to the later FDA decision timing for the second generation LungFit PH system. Analyst Commentary Bullish Takeaways Bullish analysts still frame the second generation LungFit PH system as a central driver for Beyond Air's long term revenue profile, pointing to commercialization of this product as a potential turning point for the business once regulatory milestones are met.XAIR: Bullish Coverage And New Capital Raise Will Support Future Upside
Analysts now see Beyond Air's fair value holding at $6.00 per share, with a slightly higher discount rate and modestly adjusted revenue growth, profit margin, and future P/E assumptions following fresh bullish coverage that supports a constructive long term thesis on the stock. Analyst Commentary Recent coverage frames Beyond Air as a higher risk, higher reward idea, with the current fair value estimate of US$6.00 per share sitting against a backdrop of both optimism and clear caution.XAIR: Expanded Distribution And Fresh Capital Will Support Future Upside
Analysts have kept their fair value target for Beyond Air steady at US$6.00, while adjusting their models to reflect updated assumptions on discount rate, revenue growth, profit margin and future P/E following recent bullish Street research coverage. Analyst Commentary While the latest Street coverage has been supportive, some bearish analysts continue to flag risks that they believe are not fully captured in the current US$6.00 fair value estimate.XAIR: Expanded Global Distribution And Recent Financing Will Support Future Upside
Analysts have revised their price target for Beyond Air to US$6.00, reflecting updated assumptions around the discount rate, revenue growth, profit margins and future P/E multiples, which leaves the fair value estimate unchanged at US$6.00. What's in the News Beyond Air updated its earnings guidance for the fiscal year ending March 31, 2026, with revenue now guided to a range of US$8 million to US$10 million (Corporate guidance).XAIR: Expanded Global Distribution And New Financing Will Support Upside Potential
Analysts have modestly raised their price target on Beyond Air to reflect a slightly higher long term growth outlook and valuation multiple, while incorporating a more conservative discount rate and largely unchanged profit margin assumptions. What's in the News Signed multiple new international distribution agreements for LungFit PH across Germany, Brazil, Austria, the Netherlands and Sri Lanka, bringing total coverage to 39 countries and over three billion people (Key Developments).XAIR: Stronger Revenue Outlook And Financing Will Support Future Upside Potential
Analysts have raised their price target on Beyond Air to 6.00 dollars from 5.00 dollars, citing slightly stronger expected revenue growth, modestly improved profit margins, and a higher anticipated future price to earnings multiple despite a higher discount rate. What's in the News Chief Financial Officer Doug Larson has resigned to pursue another opportunity and will remain in his role until December 5, 2025.XAIR: Global Network Expansion Will Drive Long-Term Market Presence
Analysts have modestly maintained their price target for Beyond Air at $12.33 per share. They cite steady expectations around revenue growth and profit margins, even though there have been minor adjustments to other financial assumptions.Global Expansion And Next-Generation Respiratory Care Will Transform Markets
Analysts have raised their price target for Beyond Air from $11.20 to $12.33, reflecting improved revenue growth expectations and a notable increase in projected profit margins. What's in the News The global distribution network for LungFit PH has been expanded, with new agreements in Japan, South Korea, Costa Rica, Guatemala, and El Salvador.Global Expansion And Next-Generation Respiratory Care Will Transform Markets
With minimal changes in both the discount rate and future P/E, Beyond Air’s consensus analyst price target remained effectively unchanged at $11.20. What's in the News Expanded global LungFit PH distribution network to 34 countries, including new agreements in Japan (with AMCO), South Korea, Costa Rica, Guatemala, and El Salvador.
The Next-Generation LungFit PH System Will Open New Markets
International revenue could significantly impact growth due to CE Mark approval and distribution partnerships, especially in the EU.Shareholder Returns
| XAIR | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 18.5% | -4.1% | 0.9% |
| 1Y | -86.1% | -18.2% | 28.2% |
Return vs Industry: XAIR underperformed the US Medical Equipment industry which returned -18.2% over the past year.
Return vs Market: XAIR underperformed the US Market which returned 28.2% over the past year.
Price Volatility
| XAIR volatility | |
|---|---|
| XAIR Average Weekly Movement | 14.0% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: XAIR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: XAIR's weekly volatility has decreased from 28% to 14% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 61 | Bob Goodman | www.beyondair.net |
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn.
Beyond Air, Inc. Fundamentals Summary
| XAIR fundamental statistics | |
|---|---|
| Market cap | US$6.78m |
| Earnings (TTM) | -US$31.00m |
| Revenue (TTM) | US$6.92m |
1.1x
P/S Ratio-0.2x
P/E RatioIs XAIR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XAIR income statement (TTM) | |
|---|---|
| Revenue | US$6.92m |
| Cost of Revenue | US$6.80m |
| Gross Profit | US$126.00k |
| Other Expenses | US$31.13m |
| Earnings | -US$31.00m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.35 |
| Gross Margin | 1.82% |
| Net Profit Margin | -447.73% |
| Debt/Equity Ratio | 265.2% |
How did XAIR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/04 23:10 |
| End of Day Share Price | 2026/05/04 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Beyond Air, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Gorman | BTIG |
| Marie Thibault | BTIG |
| Jason Kolbert | D. Boral Capital LLC. |